Last reviewed · How we verify
ETD002 - 7 day repeat dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ETD002 - 7 day repeat dose (ETD002 - 7 day repeat dose) — Enterprise Therapeutics Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ETD002 - 7 day repeat dose TARGET | ETD002 - 7 day repeat dose | Enterprise Therapeutics Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ETD002 - 7 day repeat dose CI watch — RSS
- ETD002 - 7 day repeat dose CI watch — Atom
- ETD002 - 7 day repeat dose CI watch — JSON
- ETD002 - 7 day repeat dose alone — RSS
Cite this brief
Drug Landscape (2026). ETD002 - 7 day repeat dose — Competitive Intelligence Brief. https://druglandscape.com/ci/etd002-7-day-repeat-dose. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab